ArticleInvestigative ophthalmology & visual science2026
PANK4 Regulates YAP to Modulate the Glycolytic Pathway in LEC for Driving LECs-EMT in Early Diabetic Cataract Pathogenesis.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Lens epithelial cell-mesenchymal transition (LEC-EMT) is the key process in diabetic cataract (DC). Although PANK4 is known to suppress LEC-EMT, its mechanism remains unclear. This study aims to elucidate the role of PANK4 in DC pathogenesis through the YAP/TAZ pathway. Methods: We established diabetic mice and high-glucose-stimulated LECs. Interventions included PANK4 overexpression/knockdown and YAP inhibitor treatment. Protein expression was analyzed by Western blotting and immunofluorescence. Anterior capsule damage was assessed via slit-lamp after anterior chamber injection of si-PANK4 or YAP inhibitor in diabetic mice. LECs' functional assays included EdU, phalloidin staining, and scratch-wound assays. Results: PANK4 and EMT markers were significantly upregulated in diabetic mice, and PANK4-overexpression upregulated EMT markers and YAP in LECs. Immunoprecipitation confirmed PANK4-YAP physical interaction in the lens. PANK4-knockdown of LECs and high-glucose-stimulated lens suppressed the expression of α-SMA and YAP, enhanced LECs' proliferation, and reduced the migration. Most importantly, si-PANK4 or YAP inhibition alleviated induced anterior capsule damage in diabetic mice. The si-PANK4 significantly downregulated EMT markers and YAP, and reversed the phosphorylation state of YAP in the lens. YAP inhibitor treatment in PANK4-overexpressing LECs similarly downregulated EMT/YAP markers and replicated the functional effects of si-PANK4 in the lens. High glucose and PANK4-overexpression upregulated HK2, LDHA, and YAP/TAZ expression, and both PANK4-knockdown and YAP inhibition reversed these effects. Conclusions: Under hyperglycemia, PANK4 activates the YAP/TAZ pathway to upregulate glycolytic enzymes (HK2/LDHA), driving LEC-EMT and early DC progression. In vivo inhibition of PANK4 or YAP alleviates anterior capsule damage, highlighting the PANK4-YAP-glycolysis-EMT axis as a promising therapeutic target for DC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.